AQR Capital Management
LXEO icon

AQR Capital Management’s Lexeo Therapeutics LXEO Stock Holding History

AQR Capital Management’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.95M Buy
339,623
+2,237
+0.7% +$15.9K ﹤0.01% 2365
2025
Q4 		$3.35M Sell
337,386
-10,537
-3% -$96.2K ﹤0.01% 1815
2025
Q3 		$2.31M Buy
347,923
+159,288
+84% +$770K ﹤0.01% 1895
2025
Q2 		$758K Buy
188,635
+138,298
+275% +$455K ﹤0.01% 2364
2025
Q1 		$175K Buy
50,337
+39,627
+370% +$176K ﹤0.01% 2916
2024
Q4 		$70.5K Buy
+10,710
New +$84.4K ﹤0.01% 2792

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management's LXEO Position: Q1 2026 in Review

AQR Capital Management increased its Lexeo Therapeutics (LXEO) stake by 0.66% in Q1 2026, buying an estimated $15.9K and bringing the position to 339,623 shares worth $1.95M. The position accounts for ﹤0.01% of the portfolio, ranked #2365.

AQR Capital Management first reported a position in LXEO in Q4 2024 and has held it in 6 quarters since. The position peaked at $3.35M in Q4 2025. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • AQR Capital Management held 339,623 shares of Lexeo Therapeutics worth $1.95M as of Q1 2026.
  • AQR Capital Management bought 2,237 Lexeo Therapeutics shares in Q1 2026, an estimated $15.9K.
  • Lexeo Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #2365 holding.
  • AQR Capital Management first reported a position in Lexeo Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • AQR Capital Management's Lexeo Therapeutics position peaked at $3.35M in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.